Williams, Wells Elected To Inovio Biomedical Board

(Comment on this article at http://www.financialwire.net/2009/10/27/williams-wells-elected-to-inovio-biomedical-board/)

October 27, 2009 (FinancialWire) -- Inovio Biomedical Corp.'s (AMEX: INO) (Current Market Cap: $123.19 Mil.) board has elected David J. Williams and Keith H. Wells as directors.

Williams is the former chairman and CEO of Sanofi Pasteur, the vaccine business of Sanofi-Aventis Group. Wells is a senior member of the Biologics Consulting Group and former director of vaccine development for The Salk Institute.

San Diego-based Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

http://www.financialwire.net

Related terms: amex, biomedical, business, cancer, ceo, consulting, dna, market, vaccine, web